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No GIB case was fatal (BARC 5a or b).  In univariate analyses, current smoking (OR 1.9, 95%CI 1.1 – 3.9, p=0.02), 
anemia at admission (OR 1.9, 95%CI 1.05 – 3.5, p=0.035), and history of malignancy (OR 2.4, 95% CI 1.2 – 5.0, p=0.02) 
were predictors of GIB.  In multivariate analyses, history of malignancy emerged as the only independent predictor of GIB 
(OR 2.3, 95% CI 1.0-5.1, p=0.049). 
Conclusion: In this unselected PCI cohort, one third of all bleedings were gastrointestinal with a frequency of 1% at one 
year. History of malignancy emerged as the only independent predictor of GIB. 
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Introduction: Current STEMI guidelines recommend the use of prasugrel in clopidogrel-naïve patients. We assessed the 
safety and efficacy of the concurrent administration of a clopidogrel and prasugrel loading dose (LD) among patients with 
acute STEMI undergoing primary PCI. 
Method: Between September 2009 and October 2012, 2,025 STEMI patients were enrolled into the randomized 
COMFORTABLE AMI trial and the SPUM ACS cohort study. Patients were divided into three groups according to type of 
peri-procedural antiplatelet loading: (1) clopidogrel and subsequent prasugrel LD [CP], (2) prasugrel LD [P] (3) clopidogrel 
LD [C]. Safety was assessed by the composite of BARC type 3, 4, and_5 bleeding and efficacy by the composite of 
cardiac death, nonfatal MI and stroke, both at 30 days. 
Results: Out of 2,025 patients, 428 (21.1%) had received CP, 447 (22.1%) P, and 1,150 (56.8%) C. At 30 days, the 
safety endpoint was observed in 1.9% of CP, 3.1% of P, and 2.9% of C patients (CP vs C adjusted HR_0.91; 95% CI 
0.40-2.03), CP vs P adjusted_HR 0.60; 95% CI 0.24-1.49). The efficacy endpoint tended to occur less frequent among CP 
compared with C patients (1.9% vs. 5.0%, adjusted_HR_0.46; 95% CI 0.20-1.06) and no difference was observed 
between CP and P patients (1.9% vs 2.9%, adjusted HR 0.55; 95% CI 0.21-1.43). 
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Conclusion: Among STEMI patients pretreated with a clopidogrel and undergoing primary PCI, the concurrent loading 
with prasugrel appears to be safe and potentially more effective than loading with clopidogrel alone. 
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